RPG Life Sciences Ltd
RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in the domestic and international market.[1]
The company is a part of RPG group which is a diversified conglomerate with interests in areas of infrastructure, tyres, information technology, pharmaceuticals, energy and plantations.[2] The group is headed by Harsh Goenka.[3]
- Market Cap ₹ 2,547 Cr.
- Current Price ₹ 1,540
- High / Low ₹ 1,740 / 745
- Stock P/E 30.1
- Book Value ₹ 203
- Dividend Yield 0.77 %
- ROCE 33.2 %
- ROE 24.2 %
- Face Value ₹ 8.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 38.4% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 30.0%
- Debtor days have improved from 36.0 to 26.6 days.
- Company's working capital requirements have reduced from 44.4 days to 32.6 days
Cons
- Stock is trading at 7.53 times its book value
- The company has delivered a poor sales growth of 8.32% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
193 | 222 | 236 | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 574 | |
175 | 206 | 224 | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 450 | |
Operating Profit | 18 | 16 | 12 | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 123 |
OPM % | 9% | 7% | 5% | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% |
1 | 2 | 66 | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | |
Interest | 7 | 7 | 3 | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 0 |
Depreciation | 10 | 10 | 11 | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 16 |
Profit before tax | 2 | 1 | 65 | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 114 |
Tax % | 51% | -717% | 18% | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | |
1 | 4 | 53 | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 85 | |
EPS in Rs | 0.51 | 2.67 | 32.29 | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 51.26 |
Dividend Payout % | 156% | 45% | 6% | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 8% |
3 Years: | 11% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 32% |
5 Years: | 38% |
3 Years: | 27% |
TTM: | 31% |
Stock Price CAGR | |
---|---|
10 Years: | 36% |
5 Years: | 44% |
3 Years: | 48% |
1 Year: | 88% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 20% |
3 Years: | 22% |
Last Year: | 24% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Reserves | 61 | 63 | 113 | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 323 |
54 | 63 | 15 | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | |
54 | 67 | 56 | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 125 | |
Total Liabilities | 183 | 206 | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 461 |
109 | 103 | 106 | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 128 | |
CWIP | 1 | 1 | 1 | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 42 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 79 |
73 | 102 | 89 | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | |
Total Assets | 183 | 206 | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 461 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 12 | -6 | -2 | 33 | 7 | 15 | 46 | 50 | 58 | 65 | 91 | |
-8 | -12 | 59 | -10 | -15 | -30 | -16 | -19 | -11 | -8 | -35 | -106 | |
-8 | -0 | -54 | 12 | -18 | 23 | 0 | -26 | -39 | -10 | -14 | -17 | |
Net Cash Flow | 0 | 0 | 0 | -0 | -0 | 1 | -1 | 0 | 0 | 40 | 17 | -32 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 57 | 81 | 56 | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 |
Inventory Days | 190 | 140 | 180 | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 |
Days Payable | 161 | 226 | 176 | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 |
Cash Conversion Cycle | 86 | -5 | 60 | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 |
Working Capital Days | 39 | 46 | 51 | 76 | 54 | 50 | 62 | 53 | 46 | 53 | 47 | 33 |
ROCE % | 7% | 6% | 2% | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% |
Documents
Announcements
-
Compliance Certificate Under Regulation 40(9)
18 Apr - Certificate issued by Practicing Company Secretary pursuant to Regulation 40 (9) of SEBI (LODR) Regulation, 2015, for the financial year ended March 31, 2024
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Certificate issued by our RTA, Link Intime India Private Limited confirming compliance under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018.
- Compliance Certificate - Regulation 7 (3) Of SEBI (LODR) Regulations, 2015 For The Period From April 1, 2023 To March 31, 2024. 15 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 8 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Oct 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2019TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Jun 2016TranscriptNotesPPT
Domestic Formulations Segment (~65% of revenues)
The company develops, manufactures, and markets branded formulations in India & Nepal. Its product portfolio includes various products which are sold under its key brands i.e. Azaron, Mofetyl, Lomitil, Arpimune, Imunotac, Serenace, etc. It has a presence in various therapeutic segments such as nephrology, rheumatology, Oncology, Orthopaedics, Gastroenterology, and others. [1]